Catalpa Ventures has introduced the primary closing of its €30 million Catalpa Well being Fund I, the primary early-stage HealthTech-focused enterprise capital fund primarily based in Luxembourg. The fund has secured commitments from entrepreneurs, household places of work and trade leaders, and is aiming for a last shut by Q1 2027. With the automobile now lively, Catalpa Ventures will start investing in early-stage HealthTech startups throughout Europe, specializing in pre-seed and seed rounds and concentrating on 15 to twenty investments over the following 4 years.
The launch comes as Europe’s healthcare methods face mounting pressures. Hospitals are more and more overstretched, medical workers shortages are intensifying, and prices proceed to rise. Europe’s ageing inhabitants additional compounds the problem, with folks aged 65 and over residing with a mean of three to 4 persistent situations. On the identical time, the World Well being Organisation initiatives a shortfall of 4 million healthcare professionals throughout Europe by 2030, spanning medical doctors, nurses and long-term care workers.
With healthcare expenditure already averaging round 10% of GDP throughout the EU and rising quicker than the broader economic system, the system’s sustainability is beneath pressure. Catalpa Ventures goals to deal with this by investing in scalable, evidence-based options able to strengthening medical capability and bettering affected person outcomes. The group has set an ambition to help improvements that enhance healthcare outcomes for no less than 100 million folks.
The fund will prioritise European founders and applied sciences in areas similar to illness prevention and administration, digital instruments that help healthcare professionals, and options that streamline workflows or scale back administrative burdens in settings together with clinics, common practices, medical analysis organisations and laboratories. Ticket sizes will vary from €300k to €1.5 million, with follow-on capability reserved for strong-performing portfolio corporations.
Catalpa Well being Fund I additionally reinforces Luxembourg’s emergence as a hub for innovation-driven healthcare funding. The fund is led by a founding group combining scientific, medical, entrepreneurial and funding experience. Univ Prof Dr med Silke Sperling brings a background spanning Max Planck, the NIH and Charité, whereas Dr Thomas Goergen contributes expertise as an entrepreneur and co-founder of Luxembourg Funding Options. They’re joined by Willibrord Ehses, former accomplice at a Luxembourg enterprise agency, and Dr Christian Goergen.
This variety of experience permits the group to conduct rigorous scientific and medical due diligence whereas supporting founders in scaling operations and demonstrating long-term influence.
“We’re constructing a platform for daring innovation and actual influence, backing tomorrow’s HealthTech leaders to remodel look after thousands and thousands,” mentioned Dr Thomas Goergen, Accomplice at Catalpa Ventures.
“As evidence-based options converge with AI at unprecedented velocity, a extremely compelling alternative emerges that the Catalpa Well being Fund is uniquely positioned to seize,” added Prof Dr med Silke Sperling, Accomplice at Catalpa Ventures.
The fund’s first funding goes to Noah Labs, a startup creating an authorized, reimbursable telemedicine platform for managing coronary heart failure. By way of superior voice analytics that help earlier detection and improved care, the corporate goals to scale back avoidable hospitalisations and set new requirements in personalised healthcare.
